Core Insights - Yidu Technology reported a total revenue of RMB 358 million for the first half of the 2026 fiscal year, representing an 8.7% year-on-year growth, with adjusted EBITDA doubling to approximately RMB 54 million [1] - The company has seen significant growth in its core business segments, with new order amounts in the big data platform and solutions segment increasing by 19.7% and the life sciences solutions segment by 61.1% [1] - The management highlighted advancements in AI technology, with applications in over 30 top-tier hospitals and a significant increase in the accuracy of its TNM staging assessment tool [1][2] Business Segment Performance - The big data platform and solutions segment generated revenue of RMB 153 million, a 14.6% increase year-on-year, providing solutions to 127 top hospitals and 44 regulatory bodies [3] - The life sciences solutions segment achieved revenue of RMB 138 million, supporting the accelerated approval of several innovative drugs and gaining recognition in real-world research [4] - The health management platform and solutions segment reported revenue of RMB 66.67 million, a 30.3% increase, with significant participation in public health insurance projects and a notable rise in active users [5] Technological Advancements - YiduCore, the company's core algorithm engine, processed over 1.3 billion patient visits and nearly 7 billion authorized medical records, covering over 10,000 hospitals [1] - The company has successfully reduced the incidence of "hallucinations" in AI models to below 1% and improved the accuracy of its TNM staging assessment tool significantly [2] - Yidu Technology received industry recognition at the CHIP 2025 conference, winning awards for its advancements in medical NLP [2]
医渡科技2026财年中期业绩：经调整EBITDA翻倍，新增订单激增，会计报表几近盈亏平衡，大模型规模落地“多点开花”